Terns Pharmaceuticals, Inc.
TERNNASDAQHealthcare
$52.95
$-0.02(-0.03%)
Market Cap$4.8B
P/E Ratio—
52W High$53.19
52W Low$2.655
Terns Pharmaceuticals, Inc. (TERN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TERN · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.10B) | ($0.09B) | ($0.09B) | ($0.06B) | ($0.05B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.02B | $0.03B | $0.01B | $0.01B |
| Change in Working Capital | ($0.00B) | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Net Cash from Operations | ($0.08B) | ($0.07B) | ($0.07B) | ($0.05B) | ($0.04B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.41B) | ($0.17B) | ($0.28B) | ($0.14B) | ($0.17B) |
| Sales of Investments | $0.11B | $0.16B | $0.24B | $0.12B | $0.05B |
| Net Cash from Investing | ($0.30B) | ($0.01B) | ($0.04B) | ($0.02B) | ($0.12B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | ($0.01B) |
| Net Cash from Financing | $0.74B | $0.16B | $0.04B | $0.17B | $0.13B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.08B) | ($0.07B) | ($0.07B) | ($0.05B) | ($0.04B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Terns Pharmaceuticals, Inc. data
About Terns Pharmaceuticals, Inc. (TERN) Cash Flow Statement
Terns Pharmaceuticals, Inc. generated operating cash flow of ($0.08B) and free cash flow of ($0.08B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
TERN · 4 questionsTerns Pharmaceuticals, Inc. generated free cash flow of ($0.08B) for 2025, down 17.3% year-over-year.
TERN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10